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Objectives. This study investigated the role of programmed
ventricular stimulation (PVS) for arrhythmia risk prediction in
patients with idiopathic dilated cardiomyopathy (IDC) and spon-
taneous nonsustained ventricular tachycardia (VT).
Background. Nonsustained VT in patients with IDC has been
associated with a high incidence of sudden cardiac death.
Methods. Over the course of 4 years, 34 patients with IDC, a left
ventricular (LV) ejection fraction <235%, and spontaneous non-
sustained VT underwent PVS. All patients were prospectively
followed for 24 6 13 months.
Results. Sustained ventricular arrhythmias were induced in 13
patients (38%). Sustained monomorphic VT was induced in three
patients (9%), and polymorphic VT or ventricular fibrillation (VF)
in another 10 patients (29%). No sustained ventricular arrhyth-
mia could be induced in 21 study patients (62%). Prophylactic
implantation of third-generation defibrillators (ICDs) with elec-
trogram storage capability was performed in all 13 patients with
inducible sustained VT or VF, and in nine of 21 patients (43%)
without inducible sustained VT or VF. There were no significant
differences between the additional use of amiodarone, d,I-sotalol,
and beta-blocker therapy during follow-up in patients with and
without inducible VT or VF. During 24 6 13 months of follow-up,
arrhythmic events were observed in nine patients (26%) including
sudden cardiac deaths in two patients and ICD shocks for rapid
VT or VF in seven patients. Arrhythmic events during follow-up
occurred in four of 13 patients with inducible ventricular arrhyth-
mias compared with five of 21 patients without inducible ventric-
ular arrhythmias at PVS (31% vs. 24%, p 5 NS).
Conclusion. PVS does not appear to be helpful for arrhythmia
risk stratification in patients with IDC, a left ventricular ejection
fraction <235%, and spontaneous nonsustained VT. Due to the
limited number of patients, however, the power of this study is too
small to exclude moderately large differences in outcome between
patients with IDC with and without inducible VT or VF.
(J Am Coll Cardiol 1998;32:739–45)
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Implantable cardiac defibrillator (ICD) therapy has recently
been shown to be superior to antiarrhythmic drugs for increas-
ing overall survival in survivors of ventricular fibrillation (VF)
or sustained ventricular tachycardia (VT) causing severe symp-
toms (1). In addition, prophylactic ICD therapy has been
demonstrated to improve survival in selected postinfarct pa-
tients with a left ventricular (LV) ejection fraction #35%,
nonsustained VT on Holter, and inducible, nonsuppressible
VT on electrophysiologic study (2). Prophylactic ICD implan-
tation at the time of elective coronary bypass surgery, however,
has failed to improve survival among patients with coronary
heart disease, a depressed LV ejection fraction, and an abnor-
mal signal-averaged electrocardiogram (ECG) (3) without
previous programmed ventricular stimulation (PVS). Thus, for
the present, electrophysiologic studies have a central role in
identifying high-risk patients with coronary artery disease in
whom prophylactic ICD implantation is indicated (2,3). In
contrast to ischemic cardiomyopathy, very little information is
available about the usefulness of PVS for arrhythmia risk
prediction in patients with nonsustained VT in the setting of
idiopathic dilated cardiomyopathy (IDC) (4–17). The purpose
of the present study, therefore, was to prospectively examine
the association between the result of PVS and subsequent
arrhythmic events in patients with IDC and spontaneous
nonsustained VT without a history of VT or VF.
Methods
Patient group. From March 1993 until February 1997, 34
out of 172 screened patients (20%) presenting with IDC at our
institution were enrolled in this study. Inclusion criteria for
study enrollment were: 1) documented nonsustained VT on
Holter with $3 consecutive ventricular premature beats with a
rate .120 bpm; 2) LV ejection fraction #35% without .50%
stenosis of any major coronary arteries during cardiac cathe-
terization; 3) LV enlargement by angiography and echocardi-
ography; and 4) absence of valvular heart disease, systemic
From the Clinical Electrophysiology Laboratory, Department of Cardiology,
Hospital of the Philipps-University of Marburg, Marburg, Germany.
Manuscript received November 19, 1997; revised manuscript received April
27, 1998, accepted May 8, 1998.
Address for correspondence: Wolfram Grimm, MD, Department of Cardi-
ology, Hospital of the Philipps-University Marburg, Baldingerstraße, 35033
Marburg, Germany.
JACC Vol. 32, No. 3
September 1998:739–45
739
©1998 by the American College of Cardiology 0735-1097/98/$19.00
Published by Elsevier Science Inc. PII S0735-1097(98)00306-4
hypertension, excessive alcohol abuse, or other conditions
known to cause cardiomyopathy. One hundred and thirty-eight
patients with IDC were excluded because they had an ejection
fraction .35% (63 patients), had no nonsustained VT on
Holter (50), had a history of sustained VT or VF (4), had
chronic amiodarone therapy (9), or did not consent to study
participation (12). In addition to diagnostic cardiac catheter-
ization with coronary angiography and left ventricular angiog-
raphy, endomyocardial biopsy was performed in 31 of 34 study
patients (91%). The histologic findings of all these patients
were abnormal, with varying degrees of hypertrophy and
fibrosis. There was no evidence for acute myocarditis or
specific heart muscle disease in any of these patients. The
clinical characteristics of the 34 study patients and the 138
screened but not enrolled patients with IDC are summarized in
Table 1.
Electrophysiologic study. Written informed consent was
obtained from all patients. Electrophysiologic studies were
performed in the nonsedated, postabsorbtive state after all
antiarrhythmic agents had been discontinued for at least five
drug half-lives. After local anesthesia had been obtained using
2% Novocaine, three 6-Fr quadripolar electrode catheters
were inserted percutaneously through the femoral veins and
advanced to the high lateral right atrium, across the tricuspid
valve to record the His bundle electrogram and to the right
ventricular apex in 26 of 34 study patients. In the remaining
eight patients with continued oral anticoagulation with couma-
dine, a single 6-Fr quadripolar electrode catheter was inserted
through the right or left basilic or cephalic vein and advanced
under fluoroscopic guidance to the right ventricular apex and
subsequently to the right ventricular outflow tract. No His
bundle recordings were obtained in the latter eight patients.
Surface electrograms from leads I, II, III, V1, and V6, and all
intracardiac recordings were displayed simultaneously on a
computer screen and continuously stored on optical disk
(CardioLab; Prucka). Measurements of time intervals were
performed manually at a screen speed of 200 mm/s. Stimula-
tion was performed with a custom-designed, programmable
stimulator (UHS 20; Biotronic) with stimuli 1 ms in duration at
two times diastolic threshold. Programmed stimulation was
performed with up to three extrastimuli at two basic drive cycle
lengths (600 or 500 ms and 400 ms), starting at the apex, then
at the outflow tract. Coupling intervals of extrastimuli were
decreased in 10-ms intervals until coupling intervals of 200 ms
were reached, refractoriness of all extrastimuli was reached, or
a sustained ventricular arrhythmia was induced. The endpoint
of stimulation was induction of a sustained ventricular arrhyth-
mia or completion of the protocol. Of note, coupling
intervals ,200 ms were not tested in order to avoid nonspecific
induction of polymorphic ventricular arrhythmias at very short
coupling intervals. When a countershock was required to
terminate an arrhythmia, no efforts were made to reproduce
this arrhythmia by PVS. Incremental ventricular pacing, LV
stimulation, or provocative maneuvers such as isuprel infusion
or antiarrhythmic drug administration were not performed in
any patient.
Definitions. Sustained VT was defined as VT .30 seconds
in duration or VT requiring countershock because of hemody-
namic collapse. Sustained VT was defined to be monomorphic,
if it had a well-defined QRS complex with constant axis and
morphology on each of the 12-lead ECG, and the VT cycle
length was $200 ms (18,19). Polymorphic VT was defined as
VT in which the QRS axis or morphology was variable from
beat to beat in at least one of the ECG leads. For the purpose
of this study, no attempts were made to differentiate polymor-
phic VT, ventricular flutter, or VF.
Follow-up. All study patients were followed prospectively
for 24 6 13 months beginning at the time of electrophysiologic
study until October 1997. Follow-up could be completed in all
34 patients. Arrhythmic events during follow-up were defined
as: 1) spontaneous sustained VT or VF; 2) appropriate ICD
shocks for spontaneous VT or VF with documentation of the
Abbreviations and Acronyms
ICD 5 implantable cardioverter defibrillator
IDC 5 idiopathic dilated cardiomyopathy
LV 5 left ventricle
PVS 5 programmed ventricular stimulation
VF 5 ventricular fibrillation
VT 5 ventricular tachycardia
Table 1. Characteristics of Study Patients and Screened but not
Enrolled Patients with IDC
Enrolled
Patients
(n 5 34)
Screened but not
Enrolled Patients
(n 5 138)
Gender (male/female) 32/2 108/30
Mean age (years) 49 6 13 50 6 13
Range 18–70 17–71
Mean LV ejection fraction (%) 25 6 6 32 6 10*
Range 15–35 9–45
NYHA functional class
Class I 3 (9%) 22 (16%)
Class II 18 (53%) 74 (54%)
Class III 13 (38%) 42 (30%)
LV end–diastolic diameter (mm) 73 6 7 69 6 9*
Range 61–87 57–102
Treatment for heart failure
Digoxin 31 (91%) 123 (89%)
Diuretics 31 (91%) 113 (82%)
ACE-inhibitors 32 (94%) 124 (90%)
Result of 24-h Holter recording
$10 ventricular premature
beats/h
19 (56%) 56 (41%)
Nonsustained VT 34 (100%) 39 (28%)*
Antiarrhythmic drug therapy (n)
Class I antiarrhythmic drugs 0 5 (4%)
d,I-Sotalol 0 4 (3%)
Amiodarone 0 24 (17%)*
History of sustained VT or VF (n) 0 11 (8%)
History of syncope (n) 6 (18%) 16 (12%)
*p , 0.05 for enrolled patients vs. screened but not enrolled patients.
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rhythm leading to the shock by stored electrograms by the
device; or 3) sudden cardiac death, i.e., death within 1 h after
the onset of symptoms in a previously medically stable patient,
death during sleep, or unwitnessed death. A total of 22 patients
(65%) underwent prophylactic ICD implantation after PVS
(Table 2). The following ICDs were used in this study:
Medtronic Jewel 7202C, 7219C, 7220C, 7221C, or 7223Cx in 16
patients, CPI Ventak P2 Cardiac Pacemakers (Guidant Cor-
poration, St. Paul, Minnesota) in four patients, and CPI
Ventak AV in the remaining two patients in whom prophylac-
tic ICD implantation was performed. All ICD systems had
antibradycardia demand pacing and biphasic shock waveforms
with a maximum shock energy of 29–34 J. For implantation of
CPI devices exclusively Endotak DSP leads were used.
Medtronic Jewel devices were implanted exclusively using
transvenous Medtronic leads (models 6936, 6934S, and 6932).
ICD implantation was completed successfully in all patients
with nonthoracotomy lead systems with a mean intraoperative
defibrillation threshold of 11 6 5 J (range 3–24 J). All ICD
patients were seen routinely in 3–4-month intervals or as soon
as possible after spontaneous shocks at our defibrillator out-
patient department for device interrogation and retrieval of
stored ECGs. An ICD discharge was considered appropriate
when stored ECGs showed an episode of sustained VT or VF
preceding the shock using previously described criteria (20).
The documented arrhythmia was considered “sustained” in the
sense that it persisted up to the point of shock delivery. Since
first shock energy was programmed to maximum output of
29–34 J in all prophylactically implanted ICDs in this study,
each arrhythmia triggering device therapy had to sustain at
least for 8–10 s before an ICD shock was delivered (Figs. 1 and
2).
Statistical analysis. All values are expressed as mean 6
standard deviation, unless stated otherwise. Comparisons be-
tween groups were made by unpaired t tests, chi-square
analysis, or Fisher’s exact test, as appropriate. A p value of
,0.05 was considered significant. Due to the small number of
patients enrolled, this study only had a 26% power (two-sided)
to detect a twofold increase in arrhythmic events in patients
with inducible VT or VF compared with patients without
inducible VT or VF based on an assumed 2-year event rate of
30% (6).
Results
Patient characteristics. Thirty-four patients with IDC, a
LV ejection fraction #35%, and spontaneous nonsustained
VT (8 6 3 beats at a rate of 180 6 26 bpm) were enrolled in
the study. The baseline characteristics of the 34 study patients
and the 138 screened but not enrolled patients are shown in
Table 1. By definition, all 34 study patients had nonsustained
Figure 1. Stored electrogram (CPI Ventak P2) of
spontaneous polymorphic VT terminated with a
34-J shock in a patient with IDC and spontaneous
nonsustained VT. Of note, sustained monomor-
phic VT had been induced in this patient.
Table 2. Characteristics of Patients with and without Inducible VT
or VF
VT/VF
Inducible
(n 5 13)
No
Inducible
VT/VF
(n 5 21)
p
Value
Baseline characteristics
Age (years) 49 6 12 49 6 13 NS
LV ejection fraction (%) 5 6 5 25 6 6 NS
NYHA I/II/III (n) 0/9/4 3/9/9 NS
LV end–diastolic diameter (mm) 73 6 7 74 6 7 NS
Length of nonsustained VT (beats) 7 6 4 8 6 3 NS
Rate of nonsustained VT (bpm) 192 6 27 173 6 23 0.04
History of syncope 2 (15%) 4 (19%) NS
Antiarrhythmic therapy following PVS
Beta-blockers 3 (23%) 4 (19%) NS
d,I-Sotalol 1 (8%) 2 (10%) NS
Amiodarone 3 (23%) 8 (38%) NS
ICD implantation 13 (100%) 9 (43%) 0.01
Follow-up duration (months) 26 6 10 23 6 14 NS
Arrhythmic events during follow-up 4 (31%) 5 (24%) NS
ICD shock for VT/VF 3 4
Sudden cardiac death 1 1
Total mortality during follow-up 3 (23%) 5 (24%) NS
Death due to heart failure 2 3
Sudden cardiac death 1 1
Noncardiac death 0 1
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VT on Holter compared with 28% of screened but not enrolled
patients (p , 0.05). In addition, enrolled patients with IDC
had a significantly lower LV ejection fraction and larger LV
end diastolic diameters compared with screened but not en-
rolled patients.
Response to PVS. Sustained monomorphic VT was in-
duced in three patients (9%), polymorphic sustained VT or VF
in 10 patients (29%), and no sustained ventricular arrhythmia
in 21 patients (62%).
Cycle length of induced monomorphic VT was 230, 240,
and 250 ms, respectively. Induction of monomorphic VT
required three extrastimuli in all three patients in whom
monomorphic VT could be induced. Due to rapid hemody-
namic deterioration, external cardioversion through preap-
plied autoadhesive pads was necessary to terminate induced
monomorphic VT in all three patients.
Polymorphic VT or VF was induced with two extrastimuli in
three patients and with three extrastimuli in the remaining
seven patients. All episodes of induced polymorphic VT or VF
had a rate .250 bpm and required external defibrillation with
200–360 J delivered through preapplied autoadhesive pads for
termination.
The baseline characteristics and antiarrhythmic therapy
following PVS of the 13 patients with inducible sustained VT
or VF and of the 21 patients without inducible VT or VF are
summarized in Table 2. His-bundle recordings were obtained
in all 26 patients in whom the electrode catheters were
introduced from the femoral veins, as described above. Mean
HV interval in these 26 patients was 66 6 13 ms (39–88 ms),
with values .55 ms in 18 of 26 patients (69%).
Prophylactic ICD implantation and device programming.
Implantation of third-generation ICDs with ECG storage
capability was performed in all 13 patients with inducible
sustained VT or VF and in nine of 21 patients (43%) without
inducible sustained VT or VF at PVS (Table 2). Since none of
the patients had pace-terminable arrhythmias induced on
electrophysiologic study, all implanted defibrillators were pro-
grammed to single-zone devices for VF detection at cycle
lengths below 312 6 13 ms (range 330–290 ms). First shock
energy was programmed to maximum output of 29–34 J in all
devices at the time of hospital discharge without any preceding
attempts of antitachycardia pacing (Figs. 1 and 2). An addi-
tional VT zone with antitachycardia pacing was programmed
active later during follow-up in one patient who developed
several episodes of pace-terminable monomorphic VT (Fig. 3).
Of note, all devices used in this study had antibradycardia
back-up pacing capability. The bradycardia escape rate was
programmed in the VVI mode (n 5 20) or in the DDD mode
(n 5 2) to 49 6 5 bpm (range 40–60 bpm).
Arrhythmic events during follow-up. During 24 6 13
months of follow-up after PVS, arrhythmic events were ob-
served in nine of 34 study patients (26%). Two patients died
suddenly, and seven patients received adequate ICD shocks for
rapid VT or VF. Sudden death occurred 1 month after hospital
discharge in one patient without inducible sustained ventricu-
lar arrhythmia at PVS. This patient had an LV ejection fraction
of 20% and was discharged from the hospital without ICD and
without antiarrhythmic drugs. Another patient with inducible
polymorphic VT on electrophysiologic testing died suddenly at
home 24 months after prophylactic ICD implantation while
waiting for heart transplantation. Unfortunately, sudden death
was unwitnessed in this patient and the device was not
available for retrieval of stored ECGs after the patient de-
ceased.
A total of seven patients experienced one or more ICD
shocks for rapid VT or VF as documented by stored ECGs by
the device (Figs. 1 and 2). Median follow-up duration between
PVS and occurrence of the first appropriate ICD shock in
these seven patients was 4 months (range 1–48 months). Mean
cycle length of the most rapid episode of VT or VF triggering
device therapy in each of the seven patients was 241 6 31 ms
(range 190–280 ms). In addition to shocks for rapid polymor-
phic VT, one patient also received shocks for spontaneous VT
with a cycle length of 300–310 ms. Therefore, antitachycardia
pacing was programmed active in this patient, which reproduc-
ibly terminated this arrhythmia (Fig. 3). Of note, sustained VT
Figure 2. Stored electrogram and marker channel (Medtronic 7202) of
spontaneous ventricular flutter (300–350 bpm) that was terminated
with a 34-J shock. Of note, no sustained ventricular arrhythmia was
inducible with up to three extrastimuli at programmed stimulation in
this patient with IDC who presented with asymptomatic nonsustained
VT on Holter. Abbreviations used in the marker channel: CD 5
cardioversion pulse; FD 5 fibrillation detection; FS 5 fibrillation
sense; VS 5 normal sense.
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below the programmed rate cut-off for VF detection of 193 6
8 bpm was not observed in any of the 22 study patients with
prophylactic ICD implantation during median follow-up of 24
months (range 4–54 months).
Relation between the result of PVS and subsequent ar-
rhythmic events. Baseline clinical characteristics and antiar-
rhythmic therapy following PVS for patients with and without
antiarrhythmic events during follow-up are summarized in
Table 3. Arrhythmic events occurred in four of 13 patients with
inducible sustained ventricular arrhythmias compared with five
of 21 patients without inducible sustained ventricular arrhyth-
mias at PVS (31% vs. 24%, p 5 NS). There was no statistically
significant difference in baseline clinical variables, result of
PVS, and antiarrhythmic therapy at the time of hospital
discharge in patients with, compared with patients without,
arrhythmic events during follow-up. The incidence of deaths
due to progressive heart failure was also not different between
patients with and without arrhythmic events. Heart transplan-
tation and dynamic cardiomyoplasty were performed in one
patient each in the patient group without arrhythmic events
until the end of follow-up in October 1997. One patient died
from progressive pancreatic carcinoma 28 months after he had
received the first appropriate defibrillator shock for ventricular
flutter.
Discussion
Prophylactic implantation of automatic defibrillators in
asymptomatic postinfarct patients with spontaneous nonsus-
tained VT, LV ejection fraction #35%, and inducible, nonsup-
pressible VT on electrophysiologic study has recently been
shown to improve survival compared with conventional antiar-
rhythmic therapy in a prospective randomized trial (2). In
contrast to postinfarct patients, arrhythmia risk stratification in
patients with spontaneous nonsustained VT in the setting of
IDC remains controversial (4–17). The present study investi-
gated the role of PVS for arrhythmia risk prediction in a
relatively homogeneous group of patients with IDC and spon-
taneous nonsustained VT in the presence of an LV ejection
fraction #35%. In contrast to previous studies investigating the
role of PVS for arrhythmia risk stratification in IDC, prophy-
lactic implantation of ICDs with ECG storage capability was
performed in the majority of patients in the present study. The
major finding of our study is that inducibility of sustained
monomorphic VT as well as inducibility of polymorphic VT or
VF at PVS failed to predict subsequent arrhythmic events, i.e.,
sustained ventricular tachyarrhythmias or sudden death, which
were observed in 26% of patients with IDC during a 2-year
follow-up. Due to the limited number of patients, however, the
power of our study is too small to exclude moderately large
differences in outcome between patients with and without
inducible VT or VF.
Figure 3. Stored electrogram and marker channel (Medtronic 7220) of
spontaneous VT (195 bpm) that was terminated by burst pacing. For
abbreviations used in the marker channel, see legend to Figure 2.
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Comparison with previous studies using PVS for arrhyth-
mia risk stratification in IDC. The results of previous studies
investigating the role of PVS for arrhythmia risk prediction in
patients with IDC without a history of sustained ventricular
tachyarrhythmias are summarized in Table 4. Similar to our
findings, sustained monomorphic VT was rarely inducible by
PVS in the majority of previous studies and most investigators
did not find PVS useful for arrhythmia risk stratification in
patients with IDC in the absence of a history of sustained VT
(4–11). The incidence of inducible sustained polymorphic VT
or VF varied between 0% in the study of Stamato et al. (5) and
29% in the present study (Table 4). This discrepancy may
simply reflect differences in patient selection and stimulation
protocol with up to two extrastimuli in the study of Stamato et
al. (5) and up to three extrastimuli in the present study.
Although the clinical significance of inducible polymorphic VT
or VF has never been evaluated in prospective studies with
sufficient power, a large body of available data suggests that
inducibility of sustained polymorphic VT or VF is merely a
nonspecific response to aggressive stimulation protocols (18).
Of note, the present study differs from previous investiga-
tions in several important aspects. In contrast to all previously
published studies (4–17), prophylactic ICD implantation with
ECG storage capability was performed in the majority of
patients with IDC and nonsustained VT following PVS. Al-
though appropriate rhythm classification based on stored
ECGs by a defibrillator can occasionally be difficult or even
impossible (20), there is no doubt that it is generally less
difficult and probably more accurate than classifying unwit-
nessed sudden death as an arrhythmic event (21,22). In
addition, only patients with “idiopathic” dilated cardiomyopa-
thy as defined above were included in our study, whereas a
variety of underlying conditions including valvular heart dis-
ease and hypertensive heart disease were enrolled as “nonisch-
emic” dilated cardiomyopathies in most previous reports.
Similar to the inclusion criteria for postinfarct patients in the
MADIT study (2), exclusively patients with IDC and sponta-
neous nonsustained VT with an LV ejection fraction #35%
were included in the present study. In contrast to MADIT,
however, syncope was not an exclusion criteria in this study.
Studies using prophylactic ICD implantation in IDC.
Whether prophylactic ICD implantation is beneficial in pa-
tients with IDC with an LV ejection fraction #30% without
previous symptomatic ventricular tachyarrhythmias is currently
being investigated in the Cardiomyopathy Trial (23,24). All
patients in the Cardiomyopathy Trial undergo extensive non-
invasive and invasive tests, including 24-h Holter monitoring
and PVS with up to three extrastimuli at two basic drive cycle
lengths (24). The Cardiomyopathy Trial is a prospectively
conducted multicenter study designed to randomize patients
with IDC in NYHA functional class II or III with a LV ejection
fraction #30% known for less than 9 months before study
Table 3. Comparison of Patients with and without Arrhythmic
Events During Follow-Up
Arrhythmic
Events
(n 5 9)
No
Arrhythmic
Events
(n 5 25)
p
Value
Baseline characteristics
Age (years) 53 6 13 48 6 13 NS
LV ejection fraction (%) 23 6 5 25 6 6 NS
NYHA I/II/III (n) 0/6/3 3/12/10 NS
Length of nonsustained VT
(beats)
9 6 3 7 6 3 0.15
Rate of nonsustained VT (bpm) 190 6 29 177 6 24 NS
History of syncope 2 (22%) 4 (16%) 0.14
Result of programmed ventricular
stimulation
No sustained VT/VF 5 (56%) 16 (64%) NS
Sustained monomorphic VT 1 (11%) 2 (8%) NS
Sustained polymorphic VT/VF 3 (33%) 7 (28%) NS
Antiarrhythmic therapy following PVS
Beta-blockers 2 (22%) 5 (25%) NS
d,I-Sotalol 1 (11%) 2 (8%) NS
Amiodarone 3 (33%) 8 (32%) NS
ICD implantation 8 (88%) 14 (56%) 0.11
Follow-up duration (months) 26 6 13 23 6 13 NS
Total mortality during follow-up 4 (44%) 4 (16%)
Death due to heart failure 1 4
Sudden cardiac death 2 0
Noncardiac death 1 0
Heart transplant/Cardiomyoplasty 0 2 (8%)
Table 4. Programmed Stimulation in Patients with Dilated Cardiomyopathy without a History of Sustained Ventricular Arrhythmias
First Author Year Pts (n) nsVT
Number of
Extrastimuli
Inducible Arrhythmias
Follow-up
(Months)
Arrhythmic Events During Follow-up
smVT pmVT/VF Ind. smVT Ind. pmVT Noninducible
Meinertz (4) 1985 42 35% 1–2 0 (0%) 1 (2%) 16 6 7 0 (0%) 0 (0%) 2 (5%)
Stamato (5) 1986 15 93% 1–2 0 (0%) 0 (0%) 19 6 4 0 (0%) 0 (0%) 2 (13%)
Poll (6) 1986 20 100% 1–3 2 (10%) 4 (20%) 17 6 14 0 (0%) 2 (50%) 5 (36%)
Das (7) 1986 24 n.a. 1–3 1 (4%) 4 (17%) 12 6 6 1 (100%) 1 (25%) 2 (11%)
Gossinger (8) 1990 32 100% 1–3 4 (13%) 0 (0%) 21 1 (25%) 0 (0%) 2 (7%)
Brembilla-Perrot (9) 1991 92 46% 1–3 3 (3%) 5 (5%) 24 6 8 2 (67%) 2 (40%) 3 (4%)
Kadish (10) 1993 43 100% 1–3 6 (14%) n.a. 20 6 14 1 (17%) n.a. 6 (16%)
Turitto (11) 1994 80 100% 1–3 10 (13%) 7 (9%) 22 6 26 3 (30%) 0 (0%) 6 (10%)
Present study 1997 34 100% 1–3 3 (9%) 10 (29%) 24 6 13 1 (33%) 3 (30%) 5 (24%)
FU 5 follow-up; Ind. 5 inducible; n.a. 5 not available; noninducible 5 no sustained ventricular arrhythmia inducible; nsVT 5 nonsustained VT; pmVT 5 sustained
polymorphic VT or VF; Pts 5 patients; smVT 5 sustained monomorphic VT; VES 5 ventricular extrastimuli.
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inclusion to either no antiarrhythmic therapy or implantation
of an ICD. Of note, neither the result of Holter monitoring nor
the result of PVS is allowed to influence randomization to ICD
versus no ICD therapy in this trial. The trial started on July 1,
1991. At the time of this writing in February 1998, the pilot
phase of the cardiomyopathy trial with enrollment of the first
100 patients has been completed, but no results have been
reported so far.
Study limitations. Due to the limited number of patients,
the power of our study is too small to exclude moderately large
differences or to demonstrate equivalence in outcome between
patients with and without inducible VT or VF at PVS with any
confidence. Another limitation of the present study is that
antiarrhythmic therapy including prophylactic ICD implanta-
tion following PVS was not standardized but left to the
discretion of the attending physician and the patient. There-
fore, it cannot be ruled out that the use of amiodarone,
beta-blockers, and d,I-sotalol influenced the outcome, al-
though there was no significant difference in the use of these
drugs in patients with and without inducible ventricular ar-
rhythmias as well as in patients with and without arrhythmic
events during follow-up (Tables 2 and 3). Since monomorphic
VT in all three patients in this study were hemodynamically not
tolerated, requiring rapid cardioversion, no catheter reposi-
tioning to optimize His-bundle recordings and no stimulation
maneuvers during VT were performed to diagnose or to rule
out bundle branch reentry as the mechanism of VT in these
patients (25). Furthermore, all ICDs used in this study pro-
vided antibradycardia demand pacing, which may have precip-
itated arrhythmias in some patients.
Clinical implications. The results of our study support the
hypothesis that PVS is not helpful for arrhythmia risk predic-
tion in patients with IDC and spontaneous nonsustained VT.
Unless larger prospective trials demonstrate that PVS might be
useful for arrhythmia risk stratification in asymptomatic pa-
tients with IDC such as the cardiomyopathy trial (23,24),
electrophysiologic testing has not been established for arrhyth-
mia risk prediction with regard to prophylactic ICD implanta-
tion in patients with IDC. Novel, preferably noninvasive risk
stratification strategies for sudden cardiac death should be
sought in patients with dilated cardiomyopathy.
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